Ohm, Thanks for the valuable information. I am

Ohm,

Thanks for the valuable information. I am still trying to understand the rationale of the decision to try cenicriviroc in COVID-9 in their ACTIV trial.

Form the paper you shared:

Quote:

---

Effects of cenicriviroc on proinflammatory cytokines

To determine whether the reciprocal increase in CCL2, CCL4, and CCL5 levels associated with the potent CCR2 and CCR5 blockade increased systemic inflammation, levels of proinflammatory cytokines were measured. IL‐6, TNF‐α, and IL‐1β levels did not change significantly in any group during cenicriviroc treatment (Supplementary Figure S1). However, participants with moderate HI had significantly higher levels of IL‐6 on Day 7 (P < 0.05) and Day 14 (P < 0.01), and significantly lower levels of TGF‐β on Day 1 (P < 0.05), Day 7 (P < 0.01), and Day 14 (P < 0.05) compared with those in matched controls (moderate). Although TGF‐β levels increased in the moderate HI group during cenicriviroc treatment (Day 1 vs. Day 14; P < 0.01), levels at Day 14 were not significantly different from those in the mild HI and matched controls (mild) groups. Therefore, it was concluded that cenicriviroc did not increase systemic inflammatory markers.[/b]

---

Mmmmm, I tough the idea in COVID is to reduce rapidly the inflammatory response not just not increase. Also, IL-6 is increased (day 7) and what one needs to reduce cytokine storm in COVID is a rapid response ...

Just does not make sense. They should be trying Leronlimab !!!!